Establishment Labs Holdings Inc. (NASDAQ:ESTA – Get Free Report)’s share price was down 5.1% during mid-day trading on Monday . The stock traded as low as $43.96 and last traded at $44.63. Approximately 510,525 shares traded hands during trading, an increase of 41% from the average daily volume of 362,609 shares. The stock had previously closed at $47.04.
Wall Street Analysts Forecast Growth
A number of research analysts recently weighed in on ESTA shares. Stephens reissued an “overweight” rating and set a $68.00 price target on shares of Establishment Labs in a research report on Wednesday, August 7th. Citigroup upped their target price on Establishment Labs from $41.00 to $45.00 and gave the stock a “neutral” rating in a research note on Thursday, August 22nd. Mizuho lifted their price target on Establishment Labs from $65.00 to $70.00 and gave the stock a “buy” rating in a research note on Thursday, June 6th. Finally, JPMorgan Chase & Co. cut their target price on Establishment Labs from $61.00 to $50.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 7th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, Establishment Labs presently has an average rating of “Moderate Buy” and an average price target of $56.60.
Read Our Latest Analysis on ESTA
Establishment Labs Price Performance
Establishment Labs (NASDAQ:ESTA – Get Free Report) last announced its earnings results on Tuesday, August 6th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.11). Establishment Labs had a negative net margin of 54.97% and a negative return on equity of 220.67%. The business had revenue of $44.12 million for the quarter, compared to analyst estimates of $43.10 million. During the same period in the prior year, the company earned ($0.65) earnings per share. The company’s quarterly revenue was down 9.2% on a year-over-year basis. As a group, equities analysts forecast that Establishment Labs Holdings Inc. will post -2.2 EPS for the current year.
Insider Activity
In other Establishment Labs news, CEO Quiros Juan Jose Chacon sold 3,866 shares of Establishment Labs stock in a transaction dated Monday, July 8th. The shares were sold at an average price of $45.01, for a total transaction of $174,008.66. Following the transaction, the chief executive officer now directly owns 215,030 shares of the company’s stock, valued at $9,678,500.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 11.44% of the company’s stock.
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in ESTA. Hood River Capital Management LLC acquired a new stake in shares of Establishment Labs during the second quarter worth about $43,000. California State Teachers Retirement System boosted its holdings in Establishment Labs by 14.5% in the first quarter. California State Teachers Retirement System now owns 17,096 shares of the company’s stock valued at $870,000 after acquiring an additional 2,167 shares during the last quarter. Swiss National Bank boosted its position in Establishment Labs by 13.6% during the 1st quarter. Swiss National Bank now owns 37,500 shares of the company’s stock worth $1,909,000 after purchasing an additional 4,500 shares during the period. Nkcfo LLC purchased a new position in Establishment Labs in the 2nd quarter worth approximately $227,000. Finally, Concurrent Investment Advisors LLC purchased a new position in Establishment Labs in the first quarter valued at about $263,000. 72.91% of the stock is currently owned by institutional investors and hedge funds.
Establishment Labs Company Profile
Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.
Read More
- Five stocks we like better than Establishment Labs
- Why Invest in 5G? How to Invest in 5G Stocks
- TJX Stock: A Buying Opportunity Before the Holiday Rush
- Conference Calls and Individual Investors
- Micron’s Blowout Results Pave the Way for Seagate’s Stock Surge
- Most Volatile Stocks, What Investors Need to Know
- Zeta Global’s AI Cloud: Your Secret Weapon for Massive Growth
Receive News & Ratings for Establishment Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Establishment Labs and related companies with MarketBeat.com's FREE daily email newsletter.